The Effect of Oral Glucose Loads on Tissue Metabolism During Angiotensin II Receptor and Beta-receptor Blockade in Obese Hypertensive Subjects

Abstract

AT1 receptor blockers and ACE inhibitors decrease the risk for new onset diabetes mellitus. The phenomenon could be related to a direct angiotensin II effect on tissue metabolism. To address the issue, we recruited eighteen obese hypertensive patients. Patients were randomized to double-blind treatment with either valsartan (n = 8) or atenolol (n = 10) for thirteen weeks. They underwent an oral glucose tolerance test before and during active treatment, while metabolism was monitored through subcutaneous and intramuscular microdialysis and indirect calorimetry. After glucose ingestion, venous glucose and insulin concentrations increased rapidly while systemic free fatty acid concentrations were suppressed. Dialysate glucose and lactate concentrations increased briskly in adipose tissue and in skeletal muscle. Dialysate glycerol decreased profoundly in both tissues. Respiratory quotient increased markedly after glucose ingestion. These responses were identical at baseline and during active treatment either drug. We conclude that AT1 receptor blockade in obese hypertensive patients has no effect on interstitial glucose supply, lipolysis, and substrate oxidation. One possible explanation is that angiotensin II levels in obese hypertensives are not sufficient to elicit the metabolic changes that have been observed after direct angiotensin II application. The exact mechanism by which inhibition of the renin-angiotensin-aldosterone system decreases the diabetes risk remains unresolved and requires further study.

Key words

Adipose tissue - angiotensin II - insulin - skeletal muscle

References

• 1 Must A, Spadano J, Coakley E H, Field A E, Colditz G, Dietz W H. The disease burden associated with overweight and obesity.  JAMA. 1999;  282(16) 1523-1529
• 2 Doll S, Paccaud F, Bovet P, Burnier M, Wietlisbach V. Body mass index, abdominal adiposity and blood pressure: consistency of their association across developing and developed countries.  Int J Obes Relat Metab Disord. 2002;  26(1) 48-57
• 3 Messerli F H, Christie B, DeCarvalho J G, Aristimuno G G, Suarez D H, Dreslinski G R. et al . Obesity and essential hypertension. Hemodynamics, intravascular volume, sodium excretion, and plasma renin activity.  Arch Intern Med. 1981;  141(1) 81-85
• 4 Tuck M L, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients.  N Engl J Med. 1981;  304(16) 930-933
• 5 Engeli S, Bohnke J, Gorzelniak K, Janke J, Schling P, Bader M. et al . Weight loss and the renin-angiotensin-aldosterone system.  Hypertension. 2005;  45(3) 356-362
• 6 Rumantir M S, Vaz M, Jennings G L, Collier G, Kaye D M, Seals D R. et al . Neural mechanisms in human obesity-related hypertension.  J Hypertens. 1999;  17(8) 1125-1133
• 7 Grassi G, Seravalle G, Dell’Oro R, Turri C, Bolla G B, Mancia G. Adrenergic and reflex abnormalities in obesity-related hypertension.  Hypertension. 2000;  36(4) 538-542
• 8 Gorzelniak K, Engeli S, Janke J, Luft F C, Sharma A M. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension.  J Hypertens. 2002;  20(5) 965-973
• 9 Massiera F, Bloch-Faure M, Ceiler D, Murakami K, Fukamizu A, Gasc J M. et al . Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation.  FASEB J. 2001;  15(14) 2727-2729
• 10 Schjoedt K J, Jacobsen P, Rossing K, Boomsma F, Parving H H. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.  Horm Metab Res. 2005;  37 Suppl 1 4-8
• 11 Scheen A J. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomised clinical trials.  Diabetes Metab. 2004;  30(6) 487-496
• 12 Boschmann M, Jordan J, Adams F, Christensen N J, Tank J, Franke G. et al . Tissue-specific response to interstitial angiotensin II in humans.  Hypertension. 2003;  41(1) 37-41
• 13 Goossens G H, Blaak E E, Saris W H, van Baak M A. Angiotensin II-induced effects on adipose and skeletal muscle tissue blood flow and lipolysis in normal-weight and obese subjects.  J Clin Endocrinol Metab. 2004;  89(6) 2690-2696
• 14 Ogihara T, Asano T, Ando K, Chiba Y, Sakoda H, Anai M. et al . Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling.  Hypertension. 2002;  40(6) 872-879
• 15 Jordan J, Tank J, Stoffels M, Franke G, Christensen N J, Luft F C. et al . Interaction between beta-Adrenergic receptor stimulation and nitric oxide release on tissue perfusion and metabolism.  J Clin Endocrinol Metab. 2001;  86(6) 2803-2810
• 16 Adams F, Jordan J, Schaller K, Luft F C, Boschmann M. Blood flow in subcutaneous adipose tissue depends on skin-fold thickness.  Horm Metab Res. 2005;  37(2) 68-73
• 17 Hickner R C, Ekelund U, Mellander S, Ungerstedt U, Henriksson J. Muscle blood flow in cats: comparison of microdialysis ethanol technique with direct measurement.  J Appl Physiol. 1995;  79(2) 638-647
• 18 Stahle L, Segersvard S, Ungerstedt U. A comparison between three methods for estimation of extracellular concentrations of exogenous and endogenous compounds by microdialysis.  J Pharmacol Methods. 1991;  25(1) 41-52
• 19 Fellander G, Linde B, Bolinder J. Evaluation of the microdialysis ethanol technique for monitoring of subcutaneous adipose tissue blood flow in humans.  Int J Obes Relat Metab Disord. 1996;  20(3) 220-226
• 20 Hickner R C, Bone D, Ungerstedt U, Jorfeldt L, Henriksson J. Muscle blood flow during intermittent exercise: comparison of the microdialysis ethanol technique and 133Xe clearance.  Clin Sci (Lond). 1994;  86(1) 15-25
• 21 Karpe F, Fielding B A, Ilic V, Humphreys S M, Frayn K N. Monitoring adipose tissue blood flow in man: a comparison between the (133)xenon washout method and microdialysis.  Int J Obes Relat Metab Disord. 2002;  26(1) 1-5
• 22 Ardilouze J L, Fielding B A, Currie J M, Frayn K N, Karpe F. Nitric oxide and beta-adrenergic stimulation are major regulators of preprandial and postprandial subcutaneous adipose tissue blood flow in humans.  Circulation. 2004;  109(1) 47-52
• 23 Clark M G, Wallis M G, Barrett E J, Vincent M A, Richards S M, Clerk L H. et al . Blood flow and muscle metabolism: a focus on insulin action.  Am J Physiol Endocrinol Metab. 2003;  284(2) E241-E258
• 24 Skilton M R, Lai N T, Griffiths K A, Molyneaux L M, Yue D K, Sullivan D R. et al . Meal-related increases in vascular reactivity are impaired in older and diabetic adults: insights into roles of aging and insulin in vascular flow.  Am J Physiol Heart Circ Physiol. 2005;  288(3) H1404-H1410
• 25 Frossard M, Joukhadar C, Steffen G, Schmid R, Eichler H G, Muller M. Paracrine effects of angiotensin-converting-enzyme- and angiotensin-II-receptor- inhibition on transcapillary glucose transport in humans.  Life Sci. 2000;  66(10) L147-L154
• 26 Boschmann M, Jordan J, Schmidt S, Adams F, Luft F C, Klaus S. Gender-Specific Response to Interstitial Angiotensin II in Human White Adipose Tissue.  Horm Metab Res. 2002;  34(11 - 12) 726-730
• 27 Cabassi A, Coghi P, Govoni P, Barouhiel E, Speroni E, Cavazzini S. et al . Sympathetic modulation by carvedilol and losartan reduces angiotensin II-mediated lipolysis in subcutaneous and visceral fat.  J Clin Endocrinol Metab. 2005;  90 (5) 2888-2897
• 28 Sharma A M, Pischon T, Hardt S, Kunz I, Luft F C. Hypothesis: Beta-adrenergic receptor blockers and weight gain: A systematic analysis.  Hypertension. 2001;  37(2) 250-254
• 29 Schiffelers S L, Saris W H, Boomsma F, van Baak M A. beta(1)- and beta(2)-Adrenoceptor-mediated thermogenesis and lipid utilization in obese and lean men.  J Clin Endocrinol Metab. 2001;  86(5) 2191-2199